Skip to Content

Extavia Approval History

FDA Approved: Yes (First approved August 14, 2009)
Brand name: Extavia
Generic name: interferon beta-1b
Treatment for: Multiple Sclerosis

Extavia is a branded version of interferon beta-1b, a first-line disease-modifying therapy that has been a standard-of-care for multiple sclerosis for many years. Extavia is indicated for the treatment of MS patients with relapsing forms of the disease and for newly diagnosed patients.

Development History and FDA Approval Process for Extavia

DateArticle
Aug 17, 2009Approval US FDA Approves Extavia - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with This Devastating Disease

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide